Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Supported Employment: Motivational Enhancement for Entry and Outcome
Supported Employment: Motivational Enhancement for Entry and Outcome
Status: Enrolling
Updated:  2/8/2016
Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA
mi
from
Bedford, MA
Supported Employment: Motivational Enhancement for Entry and Outcome
Supported Employment: Motivational Enhancement for Entry and Outcome
Status: Enrolling
Updated: 2/8/2016
Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA
mi
from
Bedford, MA
Click here to add this to my saved trials
Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence
Treatment Implications of Trauma Memory Modulation for PTSD & Alcohol Dependence
Status: Enrolling
Updated:  2/8/2016
MUSC
mi
from
Charleston, SC
Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence
Treatment Implications of Trauma Memory Modulation for PTSD & Alcohol Dependence
Status: Enrolling
Updated: 2/8/2016
MUSC
mi
from
Charleston, SC
Click here to add this to my saved trials
Anger Control Therapy (ACT) With RAGE-Control: An Outpatient Videogame-assisted Therapy for the Treatment of Anger
Anger Control Therapy (ACT) With RAGE-Control: An Outpatient Videogame-assisted Therapy for the Treatment of Anger
Status: Enrolling
Updated:  2/8/2016
Children's Hospital Boston
mi
from
Boston, MA
Anger Control Therapy (ACT) With RAGE-Control: An Outpatient Videogame-assisted Therapy for the Treatment of Anger
Anger Control Therapy (ACT) With RAGE-Control: An Outpatient Videogame-assisted Therapy for the Treatment of Anger
Status: Enrolling
Updated: 2/8/2016
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of Computerized MET for Adolescent Substance Use
Randomized Controlled Trial of Computerized MET for Adolescent Substance Use
Status: Enrolling
Updated:  2/8/2016
Boston Children's Hospital
mi
from
Boston, MA
Trial of Computerized MET for Adolescent Substance Use
Randomized Controlled Trial of Computerized MET for Adolescent Substance Use
Status: Enrolling
Updated: 2/8/2016
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery
Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery
Status: Enrolling
Updated:  2/8/2016
NYU Langone Medical Center
mi
from
New York, NY
Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery
Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery
Status: Enrolling
Updated: 2/8/2016
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Hormonal Factors in the Treatment of Anorexia Nervosa
Hormonal Factors in the Treatment of Anorexia Nervosa
Status: Enrolling
Updated:  2/9/2016
Massachusetts General Hospital
mi
from
Boston, MA
Hormonal Factors in the Treatment of Anorexia Nervosa
Hormonal Factors in the Treatment of Anorexia Nervosa
Status: Enrolling
Updated: 2/9/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Screening to Augment Referral to Treatment- Project START
Screening to Augment Referral to Treatment- Project START
Status: Enrolling
Updated:  2/9/2016
Yale-New Haven Hospital- York St Campus
mi
from
New Haven, CT
Screening to Augment Referral to Treatment- Project START
Screening to Augment Referral to Treatment- Project START
Status: Enrolling
Updated: 2/9/2016
Yale-New Haven Hospital- York St Campus
mi
from
New Haven, CT
Click here to add this to my saved trials
Screening to Augment Referral to Treatment- Project START
Screening to Augment Referral to Treatment- Project START
Status: Enrolling
Updated:  2/9/2016
Yale-New Haven Hospital-Chapel St Campus
mi
from
New Haven, CT
Screening to Augment Referral to Treatment- Project START
Screening to Augment Referral to Treatment- Project START
Status: Enrolling
Updated: 2/9/2016
Yale-New Haven Hospital-Chapel St Campus
mi
from
New Haven, CT
Click here to add this to my saved trials
Virtual Reality Therapy and Imaging in Combat Veterans With Blast Injury and Posttraumatic Stress Disorder
The ViRTICo-BP Trials: Virtual Reality Therapy and Imaging in Combat Veterans With Blast Injury and Posttraumatic Stress Disorder
Status: Enrolling
Updated:  2/9/2016
National Intrepid Center of Excellence / Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Virtual Reality Therapy and Imaging in Combat Veterans With Blast Injury and Posttraumatic Stress Disorder
The ViRTICo-BP Trials: Virtual Reality Therapy and Imaging in Combat Veterans With Blast Injury and Posttraumatic Stress Disorder
Status: Enrolling
Updated: 2/9/2016
National Intrepid Center of Excellence / Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
GETSmart: Guided Education and Training Via Smart Phones to Promote Resilience
GETSmart: Guided Education and Training Via Smart Phones to Promote Resilience
Status: Enrolling
Updated:  2/9/2016
Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center
mi
from
Bethesda, MD
GETSmart: Guided Education and Training Via Smart Phones to Promote Resilience
GETSmart: Guided Education and Training Via Smart Phones to Promote Resilience
Status: Enrolling
Updated: 2/9/2016
Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
Preventing Post-Operative Delirium in Pneumonectomy, Esophagectomy and Thoracotomy Patients
Status: Enrolling
Updated:  2/9/2016
University Hospital
mi
from
Indianapolis, IN
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
Preventing Post-Operative Delirium in Pneumonectomy, Esophagectomy and Thoracotomy Patients
Status: Enrolling
Updated: 2/9/2016
University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Open Label Trial of GLYX-13 in Individuals With Obsessive-Compulsive Disorder
Open Label Trial of GLYX-13 in Individuals With Obsessive-Compulsive Disorder
Status: Enrolling
Updated:  2/9/2016
New York State Psychiatric Insitute
mi
from
New York, NY
Open Label Trial of GLYX-13 in Individuals With Obsessive-Compulsive Disorder
Open Label Trial of GLYX-13 in Individuals With Obsessive-Compulsive Disorder
Status: Enrolling
Updated: 2/9/2016
New York State Psychiatric Insitute
mi
from
New York, NY
Click here to add this to my saved trials
Buspirone Treatment for Marijuana Dependence
Buspirone Treatment for Marijuana Dependence
Status: Enrolling
Updated:  2/10/2016
Medical University of South Carolina
mi
from
Charleston, SC
Buspirone Treatment for Marijuana Dependence
Buspirone Treatment for Marijuana Dependence
Status: Enrolling
Updated: 2/10/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
DeLand, FL
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
DeLand, FL
Click here to add this to my saved trials
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Pembroke Pines, FL
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Stockbridge, GA
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Overland Park, KA
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Las Vegas, NV
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Rochester, NY
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Raleigh, NC
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Portland, OR
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Dallas, TX
Relapse Prevention Study in Newly Abstinent Smokers
A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Garfield Heights, OH
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Garfield Heights, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Anaheim, CA
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Glendale, CA
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Imperial, CA
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Imperial, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Oakland, CA
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Oakland, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Oceanside, CA
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Pico Rivera, CA
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Pico Rivera, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
San Diego, CA
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Stanford, CA
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Hartford, CT
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Coral Springs, FL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Coral Springs, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Deerfield Beach, FL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Gainesville, FL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Maitland, FL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Maitland, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Oakland Park, FL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Oakland Park, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Orlando, FL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Tampa, FL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Chicago, IL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Joliet, IL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Joliet, IL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Naperville, IL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Naperville, IL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Oak Brook, IL
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Oak Brook, IL
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Lafayette, IN
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Lafayette, IN
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Boston, MA
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Saint Louis, MO
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials